{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:59:07Z","timestamp":1792616347484,"version":"4.5.0"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pigment Cell Melanoma Res"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple reports confirm elevated circulating IL\u201017 levels and increased numbers of Th17 lymphocytes in patients with non\u2010segmental vitiligo. Additionally, melanocyte damaging characteristics have been ascribed to IL\u201017. A single\u2010arm pilot study using secukinumab in active non\u2010segmental vitiligo was conducted. The large majority of patients developed additional skin depigmentations limiting further enrollment. Overall, laboratory analysis revealed no change in secreted chemokines or Th subsets. Th17 lymphocytes correlated with Th2, Th9, and Th22 cells while an inverse link with Th1 cells and serum sCD25 levels was observed. In contrast, Th17.1 cells correlated positively with Th1 lymphocytes. Confirmatory results were found in an independent group of patients with vitiligo showing a significant increase in Th17.1 and Th1 lymphocytes in progressive vitiligo patients compared to healthy controls, which was not found for Th17 cells. These results do not support a direct pathogenic role of IL\u201017 or Th17 cells in vitiligo. Nonetheless, a delicate Th17\/Th17.1\/Th1 balance seems evident which changes markedly according to disease activity. This may offer new treatment options by interfering with cytokines that drive differentiation of Th17 cells toward Th1.<\/jats:p>","DOI":"10.1111\/pcmr.12789","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T15:47:41Z","timestamp":1557244061000},"page":"842-847","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["IL\u201017A is not a treatment target in progressive vitiligo"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3546","authenticated-orcid":false,"given":"Reinhart","family":"Speeckaert","sequence":"first","affiliation":[{"name":"Department of Dermatology Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Mylle","sequence":"additional","affiliation":[{"name":"Department of Dermatology Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-8195","authenticated-orcid":false,"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[{"name":"Department of Dermatology Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12667"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479925"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.048"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600737"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.12.014"},{"issue":"5","key":"e_1_2_5_7_1","first-page":"508","article-title":"Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib","volume":"16","author":"Blechman A. B.","year":"2017","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxr110"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12284"},{"issue":"3","key":"e_1_2_5_10_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1684\/ejd.2013.2023","article-title":"Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non\u2010segmental vitiligo: A case\u2010 controlled study on eighty\u2010four patients","volume":"23","author":"Elela M. A.","year":"2013","journal-title":"European Journal of Dermatology"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12369"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2011.00945.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13759"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003852107"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007811"},{"issue":"21","key":"e_1_2_5_16_1","first-page":"343","article-title":"Interfering with the IFN\u2010\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi M.","year":"2015","journal-title":"Annals of Translational Medicine"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.01.004"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2366"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2015.12.040"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14416"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701242RR"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175153"}],"container-title":["Pigment Cell &amp; Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcmr.12789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pcmr.12789","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcmr.12789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T14:32:41Z","timestamp":1694269961000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcmr.12789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1111\/pcmr.12789"],"URL":"https:\/\/doi.org\/10.1111\/pcmr.12789","archive":["Portico"],"relation":{},"ISSN":["1755-1471","1755-148X"],"issn-type":[{"value":"1755-1471","type":"print"},{"value":"1755-148X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"2018-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}